IP Library Granted Patent US 9,540,423
Granted Patent B2
US 9,540,423 · App. 14/352,360 · Granted Jan 10, 2017

Plant defensins and use in the treatment of proliferative diseases

Inventors: Mark Darren Hulett (Eltham, AU); Fung Tso Lay (Reservoir, AU)
Assignees: BALMORAL AUSTRALIA PTY LTD; HEXIMA LIMITED
C07K14/415A61K38/00A61K38/168C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,423
App. No.
14/352,360
Granted
Jan 10, 2017
Kind
B2
Abstract

The present invention relates to compositions and methods for preventing or treating proliferative diseases. In particular, the present invention relates to the use of compositions derived or derivable from plants, such as plant defensins, particularly in methods for the prevention or treatment of proliferative diseases such as cancer. The present invention also relates to associated uses, systems and kits.

Claims (6)

1. A method for treating skin cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of

a polypeptide having eight canonical cysteine residues in the configuration of CyS I -CyS VIII , CyS II -CyS V , CyS III -CyS VI and CyS IV -CyS VII that (a) comprises a first amino acid sequence set forth as SEQ ID NOs: 1, 3 or 5, or (b) comprises a second amino acid sequence sharing not less than 95% identity to the first amino acid sequence, or

a host cell comprising the polypeptide; or

an isolated expression product comprising the polypeptide;

or a pharmaceutical composition comprising the polypeptide,the host cell, or the isolated expression product, together with a pharmaceutically acceptable carrier, diluent or excipient.

2. The method according to claim 1 , wherein the cancer is selected from the group consisting of basal cell carcinoma, squamous cell carcinoma, and melanoma.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2016
From: LAY, FUNG TSO
To: LA TROBE UNIVERSITY
Reel/Frame 039347/0974 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2016
From: HULETT, MARK DARREN
To: LA TROBE UNIVERSITY
Reel/Frame 039347/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2016
From: LA TROBE UNIVERSITY
To: HEXIMA LIMITED
Reel/Frame 039348/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2016
From: HEXIMA LIMITED
To: BALMORAL AUSTRALIA PTY LTD
Reel/Frame 039348/0011 →
Continuity (2)
Provisional Application 61548825 · Oct 19, 2011
Related Publication 20150158918A1 · Jun 11, 2015